University of Groningen

Innovations and paradigm shifts in atrial fibrillation ablation

Mulder, Bart A; Luermans, Justin G L M; Hindricks, Gerhard; Blaauw, Yuri

Published in:
Europace

DOI:
[10.1093/europace/euaa418](https://doi.org/10.1093/europace/euaa418)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Mulder, B. A., Luermans, J. G. L. M., Hindricks, G., & Blaauw, Y. (2021). Innovations and paradigm shifts in atrial fibrillation ablation. *Europace*, 23(Supplement_2), ii23-ii27. <https://doi.org/10.1093/europace/euaa418>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Innovations and paradigm shifts in atrial fibrillation ablation

Bart A. Mulder ^{1*}, Justin G.L.M. Luermans^{2,3}, Gerhard Hindricks⁴, and Yuri Blaauw¹

¹Department of Cardiology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; ²Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands; ³Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands; and

⁴Department of Cardiology and Electrophysiology, Leipzig Heart Institute, Leipzig, Germany

Received 20 October 2020; editorial decision 19 December 2020; accepted after revision 21 December 2020

Abstract

Treatment of symptomatic atrial fibrillation has seen important changes in the past decades. Advancements have especially been made in the field of non-pharmacological treatment of this disease. Patients in whom a rhythm control strategy is chosen the place of catheter ablation has become more frontline therapy in the past years. The procedure itself has also seen changes in technologies that can be used, either using point-by-point radiofrequency or one of the single-shot techniques. One of the major limitations that remain is that re-do procedures are often necessary due to incomplete pulmonary vein isolation and/or atrial fibrillation being initiated by other mechanisms than pulmonary vein triggers. Therefore, there is further need for developing ablation tools that reproducibly isolate the pulmonary vein transmurally. Furthermore, addressing the underlying conditions before and after catheter ablation has been shown to be of great importance. In this review, we will give an overview of the evolution of catheter ablation, highlight the latest technologies and their future endeavours, and lifestyle modifications are being discussed as part of the catheter ablation strategy.

Keywords

Atrial fibrillation • Pulmonary vein isolation • Technology • Innovations • Review

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with increased morbidity and mortality.¹ Recent AF guidelines consider pulmonary vein isolation (PVI) as first-choice treatment for maintenance of sinus rhythm and symptom improvement, especially in patients with paroxysmal AF.¹ Unfortunately, a significant proportion of patients experience AF recurrences following PVI (10–35% in the first year).^{2,3} This is of importance as repeat procedures are associated with substantial costs and potential complications. The explanation for AF recurrences following PVI is complex and multifactorial. First, with the current ablation modalities transmural ablation lesions is often not obtained and as a consequence reconduction of one or more of the pulmonary veins occurs.⁴ Secondly, many patients with AF have underlying cardiac conditions such as hypertension, heart failure, or valvular disease and in these patients marked atrial dilatation and atrial fibrosis is often present.⁵ Elimination of potentials triggers by PVI will not be

sufficient to restore and maintain long-term sinus rhythm. Consequently, if a patient experiences a recurrence of AF following ablation this could be explained by incomplete PV isolation and/or initiation and maintenance of AF by other mechanisms than PV triggers. For this reason, there is a need for further development of ablation tools that reproducibly isolate the PV with durable transmural ablation lesions. In addition, optimal patient selection based on clinical characteristics might aid in the decision whether or not the patient may benefit from PVI and ideally should guide the lesion set/ablation approach.

Ablation tools for pulmonary vein isolation

In 1998, Haissaguerre *et al.*⁶ described the role of focal drivers within the atrial muscular extensions of the pulmonary veins for initiation of AF. This pivotal paper laid the foundation of our current

* Corresponding author. Tel: +31 50 3612355. E-mail address: b.a.mulder@umcg.nl

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

understanding of AF with respect to invasive endocardial or epicardial ablation strategies. Although much remained unknown, for example, which electrophysiological and pathophysiological processes underlie these focal triggers, this hallmark paper with only 45 patients marked the beginning of a new era of invasive AF management. Currently, the cornerstone of AF ablation is PVI.¹ Especially in patients with paroxysmal AF PVI is as first-line therapy very effective with regard to AF recurrence.^{7,8} Besides eliminating PV triggers, PVI may also have anti-arrhythmic effects due to atrial debulking or to interruption of micro-re-entry at the PV ostium/antrum.⁷⁻⁹ Over the years, the importance of achieving durable PVI for maintaining sinus rhythm was supported by several observations. For example, in the GAP-AF trial, it was demonstrated that patients with incomplete PV isolation had a higher recurrence rate of AF than patients with complete PV isolation.⁴ Since there is a large number of patients referred for AF ablation there is a great need for a safe, effective ablation tool that is easy to use with short procedure times. The most widely used ablation approach is point by point circumferential ablation of the PVs using a single tip catheter with radiofrequency as energy source. The past decade several single-shot technologies have also been developed. These have the advantage of isolating the PV in one ablation attempt, rather than performing a point-by-point isolation. Examples of widely used single-shot devices are the multi-electrode circular ablation catheter, the cryoballoon catheter, and laserballoon technology (Figure 1). In the FIRE and ICE trial, a head to head comparison was evaluated between radiofrequency ‘point by point’ ablation vs. cryoballoon ablation in patients with paroxysmal AF.² This trial showed less PV reconnection at redo procedures in the cryoballoon-treated patients, and therefore needed fewer additional lesions to achieve success.¹⁰ Still, major progress is made in the understanding of lesion formation for the different ablation tools. To move the outcome of radiofrequency point-by-point, ablation forward

improvements in incorporation of impedance information, tissue contact, catheter stability, ablation time, and catheter tip temperature have been introduced.¹¹ Shorter procedure times can be achieved by high power, short duration radiofrequency point-by-point ablation (Figure 1).¹² In contrast to longer application of 60 s and 35 W, shorter application of 5–10 s with 45–50 W is being performed.¹³ Long-term follow-up is promising, however, this technique has not yet been investigated in a large randomized trial.¹³ Subsequent steps in this field are already underway which is called very high-power short duration. This strategy allows applications of 70 or 90 W.^{14,15} In the field of single-shot device, a promising technique is pulsed field ablation. Pulsed field ablation is a technique which rapidly gained interest as it has been shown to be effective in creating myocardial lesions while reducing the risk of collateral damage (Figure 1).¹⁶ It is a non-thermal ablation technique that preferentially targets myocardial tissue (in contrast to other currently used ablation tools). At present, only a small patient series has been reported: in patients with persistent AF, it appears to be feasible to perform PVI in combination with posterior wall isolation with excellent acute success.¹⁶ It is particularly reassuring that in these first attempts with pulsed field ablation it appears that no oesophageal, phrenic nerve, or pulmonary vein stenosis was encountered. Also, the lesions (both PVI and the posterior wall) appear to sustain over a short period of follow-up as assessed with a remapping procedure.¹⁶ Further studies into this novel single-shot device are definitely needed, as well as larger series, long-term follow-up, and comparison with other single-shot or point-by-point strategies. PVI can also be performed by the cardiothoracic surgeon either via a thorascopic approach as stand-alone procedure or concomitantly during open chest cardiac surgery.¹⁷ The PVs are addressed by epicardial application of a bipolar radiofrequency clamping device. The surgeon has direct visibility of the PVs and after clamping of the two jaws there is no blood flow anymore at the site

of ablation. This eliminates the heat-sink cooling effect to the tissue during ablation. This result in transmural ablation lesions with excellent durable isolation of the PVs.¹⁸

Patient selection and ablation strategy

Despite the advancements that have been made in the technological aspects of PVI in the past two decades, the success rates in patients with persistent forms of AF remain limited.¹⁹ Apart from the durability and transmural of the ablation lesion set, the outcome after PVI is affected by factors associated with the extent of the AF substrate or atrial remodelling, such as the AF type, the size of the left atrium, and relevant underlying conditions.¹ A hypothetical treatment strategy is shown in Figure 2 where additional extensive ablation options are shown with relation to a larger left atrial volume, higher AF burden, or more underlying conditions. Of course, any of these steps might be used when deemed necessary (e.g. performing a mitral isthmus line). The development of atrial disease or atrial myopathy may start years before the first initiation of AF.²⁰ This interplay between atrial myopathy and AF is based on complex interactions accelerated by risk factors as aging, inflammation, oxidative stress, and stretching of the atria.²⁰ These myopathic changes may consequently lead to disturbances in the properties of myocardial electrophysiology and the cardiac autonomic nervous system, structural changes (characterized by fibrosis), and may result in endothelial dysfunction leading to increase in pro-thrombotic state.²⁰ Therefore, it is of importance to treat the underlying conditions in as early stadium as possible to slow down the progression of AF. Several trials have shown improvement in outcome when underlying conditions are aggressively

treated. In RACE 3, this was performed in an early stadium (history of AF less than a year) and showed an improvement in sinus rhythm maintenance at one year when compared with conventional therapy.²¹ Or this may be introduced as an integral part of (pre or post) PVI management as was performed in two pivotal trials.^{22,23} In these two studies, patients received, regardless whether there was a clinical history, an aggressive risk factor management including weight management and exercise, treatment of hyperlipidaemia, obstructive sleep apnoea, hypertension, diabetes, and cessation of alcohol and smoking. These types of intervention may reverse the severity of atrial myopathy and should therefore be implemented early on.^{1,20,22,23} Optimal patient selection before PVI could potentially increase the effectiveness of AF ablation. Several clinical risk scores have been introduced in the past years to predict AF recurrences after PVI.^{24,25} The APPLE score includes underlying conditions as age, AF type, renal function, LA diameter, and left ventricular ejection fraction and has been associated with AF recurrences after a single PVI.²⁵ The DR-FLASH score has been associated with left atrial low voltage areas.²⁴ The presence of these areas, as a measure of AF substrate, has been shown to be a powerful predictor of arrhythmia recurrence after catheter ablation.²⁶ Biomarkers, like NT-proANP, have been incorporated in risk scores as well and have demonstrated good prediction of low voltage areas.²⁷ Moreover, additional imaging of the left atrium may be used to assess the left atrial substrate. An interesting study in this field was the Delayed-Enhancement MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation (DECAAF) trial.²⁸ All patients underwent a delayed enhancement MRI scan of the left atrium prior to PVI. Atrial tissue fibrosis identified by MRI was associated with increased risk for recurrent AF. Concerning optimal patient selection, the factors described above might be able to identify patients who may not benefit from

Figure 2 Hypothetical illustration of the different steps in ablation strategy in relation to underlying atrial volume, AF burden, and underlying conditions. Due to advanced disease or clinical judgement (e.g. mitral isthmus-dependent flutter) one of these steps may be performed in an earlier stadium.

PVI. Often a PVI only approach is not sufficient to maintain long-term sinus rhythm in patients with persistent forms of AF and therefore more extensive ablation has been advocated. This may include linear lesions in the atria, isolation of the LAA or of the superior vena cava, coronary sinus, ablation of complex fractionated electrograms, rotors, non-pulmonary foci, or ganglionated plexi, fibrosis-guided voltage and/or MRI-mapping, or ablation of high dominant frequency sites.^{1,29,30} However, many of these additional ablation techniques have not been investigated in a randomized fashion. Recently, it was shown that PVI in combination with ethanol infusion in the vein of Marshall, as compared with PVI alone, increased the likelihood of remaining free of AF or atrial tachycardia for 12 months.³¹ In the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II (STAR AF II), the issue of additional substrate modification was addressed. This trial showed that patients with persistent AF did not benefit from linear ablation or ablation of complex fractionated electrograms if this was performed in addition to PVI.³² An issue that remains after this trial is whether the ablation techniques used were sufficient enough to create transmural lesions. It could be that in some patients with extensive underlying conditions or increased left atrial size the primary approach should be to perform a thoracoscopic surgical ablation as higher success rates may be reached by creating transmural lesions (Figure 2).³³ Moreover, a more tailored and individualized approach might be the preferred strategy instead of creating 'one size fits all' lesions indiscriminately. Kircher et al.³⁴ demonstrated that an individually tailored substrate modification guided by voltage mapping was associated with a significantly higher arrhythmia-free survival rate compared with a conventional approach of applying linear ablation according to AF type. Comparably, one could use MRI data to incorporate into an optimal ablation strategy for any individual patient. In the Efficacy of DE-MRI-Guided Ablation vs. Conventional Catheter Ablation of Atrial Fibrillation (DECAAF II; URL: <https://www.clinical-trials.gov>. Unique identifier: NCT02529319), patients are randomized to PVI or PVI and additional fibrosis-guided ablation. Recently, a randomized trial including 155 patients randomized to MRI-guided atrial fibrosis PVI vs. conventional PVI and showed no improvement in outcome for MRI-guided PVI.³⁵ Therefore, the results of the larger DECAAF II will provide further insights whether there will remain a role for substrate ablation targeting atrial fibrosis in AF. Besides careful patient selection and an individualized AF ablation strategy, upstream therapy might improve the outcomes of AF ablation. Risk factor-driven upstream therapy refers to interventions that aim to modify the atrial substrate and also have a favourable effect on risk factors and diseases underlying AF. This was addressed in the beforementioned LEGACY and ARREST-AF studies where aggressive risk factor management conferred greater AF-free survival following catheter ablation compared with usual care.²²

Paradigm shift in the treatment of atrial fibrillation

While looking back on the innovations and paradigm shifts in AF ablation it is important to realize that treatment of AF has been focused for a long time on rate vs. rhythm control.³⁶ Since both strategies showed similar morbidity and mortality the primary goal of rhythm

control management was alleviation of AF symptoms. Recently, two contemporary rhythm control trials were published.^{37,38} In The Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial, 2204 patients with symptomatic AF were randomized to catheter ablation or medical therapy. The primary composite Endpoint of death, disabling stroke, serious bleeding was not different despite significantly fewer AF recurrences in the ablation arm.³⁷ The negative results of the intention-to-treat analysis of this study have been explained in several ways. First, high patient crossovers and event rates that were much lower than expected dampened the study's statistical power. Secondly, more than half of patients in this trial suffered persistent AF. Of note, per-protocol analyses suggested that catheter ablation-treated patients had reduced mortality compared with drug therapy. The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial EAST-AFNET 4, investigated a true early rhythm control strategy as opposed to the CABANA trial. Patients ($n = 2789$) with a short history of AF (<1 year) were randomized to early rhythm control consisting of AF ablation and AADs vs. usual care. After 2 years patients randomized to the early rhythm control had a lower risk of the primary composite outcome.³⁸ Similar to CABANA, EAST-AFNET 4 showed low event rates and the incidence of stroke was very low (0.6% early group vs. 0.9% in usual care group). Although data on AF burden are eagerly awaited, the trial showed that longer periods of sinus rhythm are associated with improved outcome. Based on these recent trials it appears that early intervention in the course of the disease by striving for sinus rhythm has prognostic benefit. As subsequently ablation is more effective in maintaining sinus rhythm compared with AAD, ablation may even move further forward towards first-line therapy.^{7,8}

Conclusion

During the past two decades, catheter-based ablation of the pulmonary veins has become standard of care for rhythm control management of symptomatic AF. Recent large randomized trial data suggest that PVI not only reduces AF burden but may also have prognostic implications. Progress is made in ablation techniques that create durable transmural ablation lesions, advancements should now be made in the appraisal and treatment of the underlying substrate of AF. Combined this may potentially lead to an individualized pre- and post-ablation approach that will improve the outcome of AF ablation.

Conflict of interest: none declared.

References

- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2020;ehaa612.
- Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR et al; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. *N Engl J Med* 2016;**374**:2235–45.
- Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG et al; STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. *J Am Coll Cardiol* 2013;**61**:1713–23.
- Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A et al; Gap-AF-AFNET 1 Investigators. Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal

- atrial fibrillation: results from the gap-atrial fibrillation-German atrial fibrillation competence network 1 trial. *Circ Arrhythm Electrophysiol* 2016;**9**:e003337.
5. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM *et al*. Lone atrial fibrillation: does it exist? *J Am Coll Cardiol* 2014;**63**:1715–23.
 6. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G *et al*. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998;**339**:659–66.
 7. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S *et al*; STOP AF First Trial Investigators. Cryoballoon ablation as initial therapy for atrial fibrillation. *N Engl J Med* 2021;**384**:316–24.
 8. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J *et al*; EARLY-AF Investigators. Cryoablation or drug therapy for initial treatment of atrial fibrillation. *N Engl J Med* 2021;**384**:305–15.
 9. Reant P, Lafitte S, Jais P, Serri K, Weerasooriya R, Hocini M *et al*. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. *Circulation* 2005;**112**:2896–903.
 10. Kuck KH, Albenque JP, Chun KJ, Furnkranz A, Busch M, Elvan A *et al*; FIRE AND ICE Investigators. Repeat ablation for atrial fibrillation recurrence post cryoballoon or radiofrequency ablation in the FIRE AND ICE Trial. *Circ Arrhythm Electrophysiol* 2019;**12**:e007247.
 11. Philips T, Taghji P, El Haddad M, Wolf M, Knecht S, Vandekerckhove Y *et al*. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the 'CLOSE'-protocol. *Europace* 2018;**20**:f419–27.
 12. Winkle RA, Mead RH, Engel G, Kong MH, Salcedo J, Brodt CR *et al*. High-power, short-duration atrial fibrillation ablations using contact force sensing catheters: outcomes and predictors of success including posterior wall isolation. *Heart Rhythm* 2020;**17**:1223–31.
 13. Baher A, Kheirkhahan M, Rechenmacher SJ, Marashly Q, Kholmovski EG, Siebermair J *et al*. High-power radiofrequency catheter ablation of atrial fibrillation: using late gadolinium enhancement magnetic resonance imaging as a novel index of esophageal injury. *JACC Clin Electrophysiol* 2018;**4**:1583–94.
 14. Kottmaier M, Popa M, Bourier F, Reents T, Cifuentes J, Semmler V *et al*. Safety and outcome of very high-power short-duration ablation using 70 W for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. *Europace* 2020;**22**:388–93.
 15. Reddy VY, Grimaldi M, De Potter T, Vijgen JM, Bulava A, Duytschaever MF *et al*. Pulmonary vein isolation with very high power, short duration, temperature-controlled lesions: the QDOT-FAST Trial. *JACC Clin Electrophysiol* 2019;**5**:778–86.
 16. Reddy VY, Anic A, Koruth J, Petru J, Funasako M, Minami K *et al*. Pulsed field ablation in patients with persistent atrial fibrillation. *J Am Coll Cardiol* 2020;**76**:1068–80.
 17. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L *et al*. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *Europace* 2018;**20**:157–208.
 18. Velagic V, DE Asmundis C, Mugnai G, Irfan G, Hunuk B, Stroker E *et al*. Repeat procedures after hybrid thorascopic ablation in the setting of longstanding persistent atrial fibrillation: electrophysiological findings and 2-year clinical outcome. *J Cardiovasc Electrophysiol* 2016;**27**:41–50.
 19. Oral H, Knight BP, Tada H, ÖZaydin M, Chugh A, Hassan S *et al*. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. *Circulation* 2002;**105**:1077–81.
 20. Shen MJ, Arora R, Jalife J. Atrial myopathy. *JACC Basic Transl Sci* 2019;**4**:640–54.
 21. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J *et al*; RACE 3 Investigators. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. *Eur Heart J* 2018;**39**:2987–96.
 22. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D *et al*. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol* 2014;**64**:2222–31.
 23. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX *et al*. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). *J Am Coll Cardiol* 2015;**65**:2159–69.
 24. Kosiuk J, Dinov B, Kornej J, Acou WJ, Schonbauer R, Fiedler L *et al*. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. *Heart Rhythm* 2015;**12**:2207–12.
 25. Kornej J, Hindricks G, Shoemaker MB, Husser D, Arya A, Sommer P *et al*. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. *Clin Res Cardiol* 2015;**104**:871–6.
 26. Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S *et al*. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. *J Am Coll Cardiol* 2005;**45**:285–92.
 27. Seewaster T, Buttner P, Zeynalova S, Hindricks G, Kornej J. Are the atrial natriuretic peptides a missing link predicting low-voltage areas in atrial fibrillation? Introducing the novel biomarker-based atrial fibrillation substrate prediction (ANP) score. *Clin Cardiol* 2020;**43**:762–8.
 28. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F *et al*. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA* 2014;**311**:498–506.
 29. Haissaguerre M, Hocini M, Takahashi Y, O'Neill MD, Pernat A, Sanders P *et al*. Impact of catheter ablation of the coronary sinus on paroxysmal or persistent atrial fibrillation. *J Cardiovasc Electrophysiol* 2007;**18**:378–86.
 30. Hayashi K, An Y, Nagashima M, Hiroshima K, Ohe M, Makihara Y *et al*. Importance of nonpulmonary vein foci in catheter ablation for paroxysmal atrial fibrillation. *Heart Rhythm* 2015;**12**:1918–24.
 31. Valderrabano M, Peterson LE, Swarup V, Schurmann PA, Makkar A, Doshi RN *et al*. Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the VENUS randomized clinical trial. *JAMA* 2020;**324**:1620–8.
 32. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R *et al*; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med* 2015;**372**:1812–22.
 33. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thorascopic surgical and transvenous catheter ablation of atrial fibrillation. *J Am Coll Cardiol* 2012;**60**:54–61.
 34. Kircher S, Arya A, Altmann D, Rolf S, Bollmann A, Sommer P *et al*. Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study. *Europace* 2018;**20**:1766–75.
 35. Bisbal F, Benito E, Teis A, Alarcon F, Sarrias A, Caixal G *et al*. Magnetic resonance imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial. *Circ Arrhythm Electrophysiol* 2020;**13**:e008707.
 36. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T *et al*. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med* 2002;**347**:1834–40.
 37. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE *et al*; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA* 2019;**321**:1261–74.
 38. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A *et al*; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med* 2020;**383**:1305–16.